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Background: Myofibroblasts play a crucial role in tissue repair. The functional similarities and differences between
myofibroblasts and fibroblasts are not fully understood because they have not been separately isolated from a
living body. The purpose of this study was to establish a method for the direct isolation of myofibroblasts and
fibroblasts from injured lungs by using fluorescence-activated cell sorting and to compare their functions.
Results: We demonstrated that lineage-specific cell surface markers (lin), such as CD31, CD45, CD146, EpCAM
(CD326), TER119, and Lyve-1 were not expressed in myofibroblasts or fibroblasts. Fibroblasts of bleomycin-injured
lungs and saline-treated lungs were shown to be enriched in linneg Sca-1high, and myofibroblasts of bleomycin-
injured lungs were shown to be enriched in linneg Sca-1low CD49ehigh. Results from in-vitro proliferation assays
indicated in-vitro proliferation of fibroblasts but not myofibroblasts of bleomycin-injured lungs and of fibroblasts of
saline-treated lungs. However, fibroblasts and myofibroblasts might have a low proliferative capacity in vivo. Analysis
of genes for collagen and collagen synthesis enzymes by qRT-PCR showed that the expression levels of about half
of the genes were significantly higher in fibroblasts and myofibroblasts of bleomycin-injured lungs than in
fibroblasts of saline-treated lungs. By contrast, the expression levels of 8 of 11 chemokine genes of myofibroblasts
were significantly lower than those of fibroblasts.
Conclusions: This is the first study showing a direct isolation method of myofibroblasts and fibroblasts from injured
lungs. We demonstrated functional similarities and differences between myofibroblasts and fibroblasts in terms of
both their proliferative capacity and the expression levels of genes for collagen, collagen synthesis enzymes, and
chemokines. Thus, this direct isolation method has great potential for obtaining useful information from
myofibroblasts and fibroblasts.
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When a tissue is injured, a sequence of events leads to
the repair of the injured tissue. Tissue repair (wound
repair) occurs in three overlapping phases, the inflam-
matory, proliferative, and remodeling phases [1]. In the
inflammatory phase, leukocytes, such as neutrophils,
lymphocytes, and monocytes, are recruited to clear the
wound of dead cells. In the proliferative phase, angio* Correspondence: toshiiwa@hama-med.ac.jp
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reproduction in any medium, provided the orgenesis and collagen deposition occurs, and the injured
tissue is replaced with granulation tissue, which is com-
posed of endothelial cells, pericytes, fibroblasts, myo-
fibroblasts, leukocytes, and extracellular matrix. In the
remodeling phase, repair of the injured tissue can be ac-
complished by the regeneration of parenchymal cells of
the same type or replacement by fibrous extracellular
matrix.
Myofibroblasts found in both the proliferative and re-
modeling phases play an important role in producing
extracellular matrix, including collagen, and are defined
as fibroblast-like cells that express α-smooth muscleral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and























































































































Figure 1 Characterization of the bleomycin-injured lung model.
(A) Mice (solid line, N = 10) were intratracheally administered
bleomycin. In mice treated with bleomycin, mortality was as high as
70% by day 12. (B) Saline-treated lungs at day 12 (N = 3) and
bleomycin-injured lungs at day 12 (N = 3) were homogenized at the
same time. Hydroxyproline content was higher in bleomycin-injured
lungs at day 12 than in saline-treated lungs. Results represent the
mean (± s.d.) of three experiments. (C) BAL fluid of saline-treated
lungs (N = 3) was collected at day 12. BAL fluid of bleomycin-treated
lungs was collected at days 3 (N = 3), 6 (N = 3), and 12 (N = 5). IL-6
and TGF-β1 concentration in BAL fluid at days 3, 6, and 12 was
significantly higher than that of saline-treated lungs. Results
represent the mean (± s.d.) of three or five experiments. (D) Total
and differential cell count in BAL fluid of mice treated by bleomycin
or saline (dashed line). BAL fluid of saline-treated lungs was
collected at days 12 (N = 3). BAL fluid of bleomycin-treated lungs
was collected at days 3 (N = 3), 6 (N = 3), and 12 (N = 5). Dashed
line indicates the average of BAL fluid of saline-treated lungs. Results
represent the mean (± s.d.) of three or five experiments. *, P < 0.05;
**, P < 0.001; ***, P < 0.0001. BAL, bronchoalveolar lavage; s.d.,
standard deviation.
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scope indicated that myofibroblasts have morphological
characteristics similar to those of both fibroblasts and
smooth muscle cells [11]. However, except for the con-
tractility of myofibroblasts, functional similarities and
differences between fibroblasts and myofibroblasts have
not been fully elucidated [12,13].
Fibroblasts in culture differentiate into α-SMA-positive
myofibroblast-like cells with increased expression of type
1 collagen in the presence of transforming growth factor
β (TGF-β), which is a strong profibrotic factor [14-16].
Many genes involved in the regulation of myofibroblast
differentiation have been studied in models of in-vitro
differentiation [17-20]. However, it is unclear whether
cultured myofibroblast-like cells have the same nature as
myofibroblasts present in vivo because the gene expres-
sion pattern might be altered during culture. Therefore,
the direct isolation of myofibroblasts and fibroblasts
from the living body is necessary for comparison of their
functions. To our knowledge, no study has shown a dir-
ect isolation method of myofibroblasts and fibroblasts
from injured tissue because these cells lack specific cell
surface markers that distinguish them from other cells
when using fluorescence-activated cell sorting (FACS).
In this study, we used a combination of cell surface
markers to isolate myofibroblasts and fibroblasts from
bleomycin-injured lungs in the proliferative phase. Fur-
thermore, we found that fibroblasts of bleomycin-injured
lungs and saline-treated lungs proliferated in vitro, while
myofibroblasts of bleomycin-injured lungs did not pro-
liferate in vitro. In addition, we compared the expression
levels of genes for collagen, collagen synthesis enzymes,
and chemokines of directly isolated myofibroblasts and
fibroblasts. We found that the expression levels of genes
for collagen and collagen synthesis enzymes were similar
between myofibroblasts and fibroblasts of bleomycin-
injured lungs, whereas the expression levels of chemokine
genes were reduced in myofibroblasts. These results indi-
cated that the function of myofibroblasts differs from that
of fibroblasts in bleomycin-injured lungs.
Results
Characterization of the bleomycin-injury lung model
In the bleomycin-injury lung model used in this study
(intratracheal administration of bleomycin 2 mg/kg to
10- to 12-week-old mice), the mortality was as high as
70% by day 12 (Figure 1A). To reduce the number of
mice used for experiments, bleomycin-injured lungs of
mice at day 12 were used throughout this study. The hy-
droxyproline content of bleomycin-injured lungs of day
12 was higher (1.3-fold higher, P < 0.05) than that of
saline-treated lungs (Figure 1B). The content of TGF-β1
in bronchoalveolar lavage (BAL) fluid of bleomycin-
injured lungs at day 12 was significantly higher thanthose of bleomycin-injured lungs at day 3 and saline-
treated lungs (Figure 1C). These results indicated that
collagen deposition had occurred concomitantly with
the increased levels of TGF-β1 in bleomycin-injured
lungs of day 12.
The content of IL-6, a pro-inflammatory cytokine, of
bleomycin-injured lungs at day 12 was comparable to
those of bleomycin-injured lungs at days 3 and 6. The
percentage of neutrophils in BAL fluid of bleomycin-
injured lungs at day 12 was significantly decreased com-
pared with those of bleomycin-injured lungs at day 6,
whereas the percentage of lymphocytes in BAL fluid of
bleomycin-injured lungs at day 12 reached was around
50% (Figures 1C and D). These results indicated that the
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inflammatory response continued in bleomycin-injured
lungs at day 12.
Extensive lung fibrosis typically occurs around days 21
to 28 in the remodeling phase after intratracheal admin-
istration of bleomycin [21,22]. Thus, we hypothesized
that the collagen deposition found in bleomycin-injured
lungs of day 12 occurred in the proliferative phase, be-
tween the inflammatory phase and remodeling phase.
Myofibroblasts expressed type 1 collagen in bleomycin-
injured lungs
The expression of α-SMA was examined immunohisto-
chemically in saline-treated lungs and bleomycin-injured
lungs. Except for vascular and bronchial smooth muscle
cells, α-SMA-positive cells were not found in saline-
treated lungs (Figure 2B). On day 12 after administration
of bleomycin, α-SMA-positive myofibroblasts were found
in lungs. Type 1 collagen A1 (Col1A1), which is a compo-
nent of type 1 collagen, was localized primarily in the
perivascular area (adventitia) in saline-treated lungs
(Figure 2C). Weak immunoreactivity of Col1A1 was found
















Figure 2 Myofibroblasts expressed type 1 collagen in
bleomycin-injured lungs. Saline-treated lungs were fixed in
formalin and examined by H & E stain (A) and using anti-α-SMA
antibody (B) and anti-Col1A1 antibody (C). 12 days after bleomycin
had been administered, bleomycin-injured lungs fixed in formalin
were examined by H & E stain (D) and using anti-α-SMA antibody
(E) and anti-Col1A1 antibody (F). Snap-frozen bleomycin-injured
lungs at day 12 were fixed in cold acetone and examined by
immunofluorescence using anti-α-SMA antibody (G) and anti-Col1A1
antibody (H), and these latter two images were merged with
nuclear stain using DAPI (I). Asterisk and arrow indicate pulmonary
and bronchial epithelium, respectively. In (G), (H), and (I), arrows
indicate cells that were α-SMA- and Col1A1 double-positive. The
asterisk indicates Col1A1 in the interstitial space. Figures show
representative results. Scale bars in (A to F) indicate 200 μm. Scale
bars in (G to I) indicate 100 μm. α-SMA, α-smooth muscle actin;
Col1A1, collagen 1A1, DAPI, 4´,6-diamidino-2-phenylindole.vascular smooth muscle cells partly produce type 1 colla-
gen, as previously reported (data not shown) [23,24].
Strong immunoreactivity of Col1A1 was detected in re-
gions where myofibroblasts were found in bleomycin-
injured lungs at day 12 (Figure 2E). Immunofluorescence
analysis using antibodies against α-SMA and Col1A1
demonstrated that myofibroblasts produced collagen 1A1
in bleomycin-injured lungs at day 12 (Figures 2G,H, and I).
These results indicated that in bleomycin-injured
lungs, type 1 collagen was primarily produced by
myofibroblasts and perivascular fibroblasts, whereas in
saline-treated lungs, type 1 collagen was primarily pro-
duced by perivascular fibroblasts.Lineage-specific cell surface markers were not expressed
in myofibroblasts or perivascular cells
To isolate myofibroblasts and fibroblasts from bleomy
cin-injured lungs at day 12, many cell types should be
eliminated when using FACS. Lungs are composed of
many types of cell: epithelial cell adhesion molecule
(EpCAM)-positive epithelial cells, CD31-positive vascu-
lar endothelial cells, lymphatic vessel endothelial hya-
luronan receptor (Lyve-1)-positive lymphatic endothelial
cells, TER119-positive erythrocytes, CD45-positive leu-
kocytes, fibroblasts, myofibroblasts, pericytes, mesothe-
lial cells, cartilage cells, and adipocytes. Adipocytes and
cartilage cells can easily be excised because they are lo-
cated primarily in the hilum of the lung.
Neuron-glial antigen 2 (NG2), but not α-SMA, is
expressed in pericytes in mouse capillary vessels, as pre-
viously reported [25]. NG2 was specifically expressed in
pericytes and vascular smooth muscle cells in lungs of
NG2DsRedBAC transgenic mice (in Additional file 1:
Figure S1A). Analysis by immunohistochemistry and
flow cytometry showed that CD146 was expressed on the
cell surface of most NG2-positive cells of these transgenic
mice (in Additional file 1: Figure S1B and Additional file 1:
Figure S2). Moreover, CD146 was expressed in bronchial
smooth muscle cells (in Additional file 1: Figure S1C).
These results demonstrate that CD146 is a lineage-specific
cell surface marker of pericytes, vascular smooth muscle
cells, and bronchial smooth muscle cells.
We used immunofluorescence analysis to demonstrate
that perivascular cells and α-SMA-positive myofibroblasts
were negative for lineage-specific cell surface markers
(CD31, CD45, CD146, EpCAM, Lyve-1, and TER119), as
shown in Figures 3A and B.Myofibroblasts and fibroblasts were enriched in linneg
cells of saline-treated lungs and bleomycin-injured lungs
The results of our immunofluorescence analyses (Figures 3A
and B) support the hypothesis that myofibroblasts and fi-
broblasts are enriched in the fraction that was negative for




























Figure 3 Lineage-specific cell surface markers were not
expressed in myofibroblasts or perivascular cells. (A) Snap-
frozen bleomycin-injured lungs at day 12 were fixed in acetone and
examined by immunofluorescence using FITC-conjugated antibodies
to lineage-specific cell surface markers (CD31, CD45, EpCAM, TER119,
CD146, and Lyve-1) (left) and anti-α-SMA antibody (middle); these
two images were merged with DAPI (blue in right). Figures show
representative results. Scale bars indicate 100 μm. (B) Snap-frozen
saline-treated lungs were fixed in acetone and examined by
immunofluorescence with DAPI (left) and FITC-conjugated
antibodies to lineage-specific cell surface markers (CD31, CD45,
EpCAM, TER119, CD146, and Lyve-1) (middle); these two images
were merged (right). Arrows indicate a cell that was localized in the
adventitia of the pulmonary artery and that was negative for
lineage-specific cell surface markers. The asterisk indicates the
pulmonary artery. Figures show representative results. Scale bars
indicate 50 μm. (C) Single lung cells, as shown in Additional file 1:
Figure S3 were plotted for APC-conjugated anti-CD31, CD45, EpCAM,
and TER119 antibodies vs. FITC-conjugated anti-CD146 and Lyve-1
antibodies. Unfractionated cells were sorted from the square in the
figure. Linneg cells were sorted from the APC and FITC double-
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Figure 4 Myofibroblasts and fibroblasts were enriched in linneg
cells of saline-treated lungs and bleomycin-injured lungs. (A)
Expression levels of Acta2 and Col1a1mRNA were compared among
unfractionated cells of saline-treated lungs, linneg cells of saline-
treated lungs, unfractionated cells of bleomycin-injured lungs at day
12, and linneg cells of bleomycin-injured lungs at day 12 using qRT-
PCR. Results were normalized to expression levels of unfractionated
cells of saline-treated lungs. QRT-PCR was performed in triplicate
using three independently prepared RNA samples. Results represent
the mean (± s.d.) of three experiments. *, P < 0.01. (B) Expression
levels of intracellular α-SMA were compared between linneg cells of
bleomycin-injured lungs at day 12 (left) and linneg cells of saline-
treated lungs (right) using FITC-conjugated anti-α-SMA antibody. As
shown in Figure 2C, 10,000 sorted linneg cells were fixed in 10%
formalin and then permeabilized and incubated with mouse FITC-
conjugated isotype control antibody (IgG2a) or FITC-conjugated anti-
α-SMA antibody. The fluorescence intensity of FITC-α-SMA (black
line) or FITC-conjugated isotype control (gray line) of linneg cells is
shown. Figures show representative results. Unfrac, unfractionated;
s.d., standard deviation.
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(linneg cells) (Figure 3C and Additional file 1: Figure S3).
To confirm the hypothesis, gene expression levels
of Col1a1 (a fibroblast and myofibroblast marker)
and Acta2 (a gene encoding α-SMA) were compared
between unfractionated cells and linneg cells, using qRT-
PCR. In saline-treated lungs, Acta2 and Col1a1 ex-
pression levels of linneg cells were 2.9-fold and 112.5-
fold higher than corresponding levels in unfractionated
cells (Figure 4A). In bleomycin-injured lungs at day 12,
Acta2 and Col1a1 expression levels of linneg cells were
11.7-fold and 121.5-fold higher than corresponding
levels in unfractionated cells (Figure 4A). Quantification
of vimentin (a mesenchymal cell marker) by flowcytometry showed that vimentin was expressed in most
linneg cells of saline-treated lungs and bleomycin-injured
lungs of day 12 (data not shown), suggesting that linneg
cells did not contain epithelial cells but consisted pri-
marily of fibroblasts and myofibroblasts. Quantification
of α-SMA by flow cytometry showed that approximately
25% of linneg cells of bleomycin-injured lungs expressed
high levels of α-SMA and that the remaining 75% of
linneg cells of bleomycin-injured lungs at day 12 and
most linneg cells of saline-treated lungs expressed low
levels of α-SMA (Figure 4B).
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(α-SMAhighCol1a1high) and fibroblasts (α-SMAlowCol
1a1high) were enriched in linneg cells of bleomycin-
injured lungs of day 12 and that fibroblasts (α-
SMAlowCol1a1high) were enriched in linneg cells of
saline-treated lungs.Exploring cell surface markers of myofibroblasts and
fibroblasts
To investigate cell surface markers that are highly
expressed in myofibroblasts, we generated cDNA of
linneg cells of bleomycin-injured lungs at day 12 and
performed quantitative PCR for 114 genes of cell surface
markers ( in Additional file 1: Table S2), for which anti-
bodies were commercially available for flow cytometry,
and measured the cycle threshold (Ct) of each gene
(Table 1). The cycle threshold is defined as the number
of cycles that were required for the fluorescent signal to
cross the threshold. Because a low Ct implies that theTable 1 Exploring cell surface markers of myofibroblasts
Gene ΔCt Gene ΔCt Gene ΔCt Gene ΔCt Gene ΔCt
CD49e 3.2 CD276 6.6 CD117 10.0 CD127 12.5 CD48 14.4
CD120a 3.4 CD126 7.2 CD123 10.0 CD195 12.5 CD135 14.5
CD44 3.4 CD95 7.2 CD157 10.1 CD197 12.7 CD72 14.5
CD29 3.5 CD36 7.5 CD274 10.2 CD253 12.8 CD278 14.6
Sca1 4.4 CD49b 7.8 CD283 10.3 CD53 12.8 CD21 14.7
CD140a 4.4 CD13 7.9 CD73 10.3 CD103 13.0 CD212 14.7
CD107a 5.2 CD202b 7.9 CD80 10.4 CD104 13.1 CD279 14.8
CD140b 5.2 CD275 7.9 CD133 10.5 CD137 13.1 CD62L 14.9
CD119 5.3 CD14 8.0 CD180 10.5 CD162 13.3 CD69 15.0
CD147 5.3 CD284 8.2 CD282 10.7 CD210 13.3 CD94 15.0
CD54 5.4 CD49a 8.3 CD61 10.8 CD265 13.3 CD178 15.1
CD81 5.4 CD90 8.3 CD93 10.9 CD28 13.4 CD193 15.1
CD47 5.6 CD200 8.4 CD115 11.0 CD86 13.4 CD152 15.5
CD106 6.0 CD24 8.4 CD121b 11.0 CD62E 13.5 CD23 15.5
CD121a 6.0 CD71 8.5 CD153 11.5 CD62P 13.5 CD25 15.6
CD172a 6.0 CD262 8.5 CD49f 11.5 CD150 13.9 CD254 15.8
CD266 6.1 CD40 8.9 CD102 12.0 CD22 13.9 CD273 15.9
CD51 6.1 CD107b 9.0 CD26 12.0 CD122 14.1 CD30 15.9
CD9 6.2 CD34 9.0 CD43 12.2 CD134 14.1 CD38 16.0
CD98 6.3 CD55 9.1 CD88 12.3 CD16 14.2 CD70 16.8
CD105 6.5 CD18 9.2 CD45 12.4 CD244 14.2 CD154 16.9
CD124 6.5 CD184 9.5 CD49d 12.4 CD252 14.2 CD207 17.0
CD206 6.5 CD223 9.9 CD100 12.5 CD27 14.3
Quantitative PCR was performed using two independently prepared cDNA
samples of linneg cells of bleomycin-induced lungs at day 12. ΔCt, the Ct of a
gene of the sample minus the number of Ct of Actb (actin, beta) of the
sample. Results represent the mean of two experiments.gene is expressed at high levels, gene expression levels
can be estimated from the Ct [26].
The expression levels of 13 genes with low Ct value
were compared between linneg cells of bleomycin-injured
lungs at day 12 and linneg cells of saline-treated lungs
using QRT-PCR, to identify cell surface markers that
could be used to distinguish myofibroblasts from fibro-
blasts (Table 2). We found that CD49e, CD44, CD54,
and Sca-1 were differentially expressed between these
two cell types (fold change > 2 or < 0.5, and P < 0.05).
Immunofluorescence analysis using antibodies against
CD49e (fold change: 5.50) and Sca-1 (fold change: 0.44)
demonstrated that Sca-1 was expressed in perivascular
cells, whereas CD49e, but not Sca-1, was expressed in
myofibroblasts in bleomycin-injured lungs (Figures 5A
and B). In saline-treated lungs, Sca-1 was expressed in
perivascular cells, which were negative for lineage-
specific cell surface markers. Our data are consistent
with a previous study showing that Sca-1 is expressed in
perivascular fibroblasts in normal lung tissue [27].
Because lineage-specific cell surface markers (CD31,
CD45, CD146, EpCAM, Lyve-1, and TER119) were not
expressed in mesothelial cells, flat epithelial-like cells
on the lung surface, we were concerned that linneg cells
might contain many mesothelial cells. However, im-
munofluorescence analysis using anti-CD49e and anti-
Sca-1 antibodies showed that CD49e and Sca-1 were
expressed in mesothelial cells at very low levels
(Additional file 1: Figure S4), indicating that mesothelial
cells can be excluded when anti-CD49e and anti-Sca-1
antibodies are used for the isolation of myofibroblasts
and perivascular fibroblasts using FACS.
Identification of myofibroblast-rich and fibroblast-rich
populations
Analysis by flow cytometry showed expression levels of
CD49e and Sca-1 of linneg cells of bleomycin-injured
lungs at day 12 and saline-treated lungs (Figure 6A).
Most linneg cells of saline-treated lungs expressed Sca-1
at high levels. Conversely, two-thirds of linneg cells of
bleomycin-injured lungs expressed Sca-1 at low levels;
the remaining cells expressed Sca-1 at high levels. Linneg
Sca-1high cells (population A) were sorted from saline-
treated lungs, and linneg Sca-1high cells (population B),
linneg Sca-1low CD49ehigh cells (population C), and linneg
Sca-1low CD49elow cells (population D) were sorted from
bleomycin-injured lungs, by FACS. The expression levels
of α-SMA of each population were then quantified by
flow cytometry. Figure 6B shows that most cells in popu-
lation C expressed α-SMA at high levels, whereas most
cells in the other populations expressed α-SMA at low
levels. These results indicated that most cells in popula-
tion C were myofibroblasts and most cells in populations
A, B, and D were not myofibroblasts.
Table 2 Identification of cell surface markers
distinguishing myofibroblasts and fibroblasts
Gene ΔCt of linneg
of saline-
treated lungs
ΔCt of linneg of
bleomycin-injured
lungs of day 12
ΔΔCt Fold change
(Bleo/saline)
CD49e 9.7 6.8 −2.9 5.50*
CD44 8.4 7.0 −1.4 2.28*
CD29 7.9 7.1 −0.8 1.60
CD140b 8.8 8.8 0.0 1.00
CD147 8.8 8.9 0.1 0.94
CD120a 6.8 7.0 0.2 0.89
CD140a 7.5 8.0 0.5 0.75
CD107a 8.2 8.8 0.6 0.70
CD47 8.4 9.2 0.8 0.62*
CD81 8.0 9.0 1.0 0.56*
CD119 7.8 8.9 1.1 0.52*
CD54 7.7 9.0 1.3 0.47*
Sca-1 6.6 8.0 1.4 0.44*
ΔCt = Ct of a gene of the sample minus Ct of 18 s rRNA of the sample. ΔΔCt =
ΔCt of linneg of bleomycin-injured lungs at day 12 minus ΔCt of linneg of
saline-treated lungs. Calculation for fold change in gene levels between
bleomycin-injured lungs at day 12 and saline-treated lungs (bleomycin/saline)
is described in Methods. QRT-PCR was performed in triplicate using three
independently prepared RNA samples. Results represent the mean of three
experiments. *, P < 0.05.
Akamatsu et al. Fibrogenesis & Tissue Repair 2013, 6:15 Page 6 of 17
http://www.fibrogenesis.com/content/6/1/15The sorted cells from populations A, B, C, and D were
grown on culture plates. On day 1 after sorting, the ex-
pression levels of α-SMA and vimentin were analyzed
immunocytochemically. As shown in Figure 6C, most
adherent cells of populations A, B, and D were α-
SMA-negative or showed low expression levels, but
were vimentin-positive. In addition, all adherent cells of
populations A, B, and D spontaneously differentiated into
α-SMA-positive myofibroblast-like cells after 7 days of cul-
ture in the presence or absence of TGF-β (data not shown)
as previously reported [28], suggesting that adherent cells
of populations A, B, and D were originally fibroblasts. Most
adherent cells of population C were α-SMA-positive
(Figure 6C), demonstrating that they were myofibroblasts.
We did not detect any CD31-positive endothelial cells,
CD146-positive pericytes, EpCAM-positive epithelial cells,
calretinin-positive mesothelial cells, CD45-positive macro-
phages, or dendritic cells among the adherent cells of popu-
lations A, B, C, and D by immunocytochemical analysis
(data not shown).
These findings indicated that fibroblasts were highly
enriched in populations A and B and that myofibroblasts
were highly enriched in population C. Because the num-
ber of adherent cells of population D was much smaller
than that of the other populations, we did not investigate
them further.In-vitro and in-vivo proliferative capacity of
myofibroblasts and fibroblasts
To examine their in-vitro proliferative capacity, the ad-
herent cells of each population were counted on days 1,
4, 7, and 10 after FACS (Figure 7A). Interestingly, fibro-
blasts of saline-treated lungs and bleomycin-injured
lungs at day 12 proliferated, whereas myofibroblasts of
bleomycin-injured lungs at day 12 did not proliferate
in vitro.
To assess the in-vivo cell-cycle status, we performed
a quantitative cell-cycle assay using Hoechst 33342
(Figure 7B). The proportion of cells in the G2M phase of
populations A, B, and C was similar (1.5%, 0.9%, and
2.2%, respectively), but was markedly lower than that of
lineage-specific cell surface marker-positive cells in
saline-treated lungs (Figure 7B) and bleomycin-injured
lungs (data not shown).
Therefore, we concluded that fibroblasts and myo-
fibroblasts had low proliferative capacity in vivo, and
that fibroblasts of bleomycin-injured and saline-
treated lungs proliferated in vitro, but myofibroblasts
of bleomycin-injured lungs did not proliferate in vitro.
Expression profiling of genes for collagen, collagen
synthesis enzymes, and chemokines of myofibroblasts
and fibroblasts
The expression of genes for collagen and collagen syn-
thesis enzymes of directly isolated myofibroblasts and
fibroblasts was investigated. The pathway of the post-
translational modification of collagen is described else-
where [29,30]. In short, after having been catalyzed by
intracellular enzymes, that is, prolyl 4-hydroxylase (P4h),
procollagen lysyl hydroxylase (Plod), and heat shock
protein 47, procollagen produced by fibroblasts and
myofibroblasts is catalyzed by a procollagen proteinase
(Adamts 2) and lysyl oxidase (Lox) or members of the
Lox-like (Loxl) family, after which collagen fibrils are
formed.
By using qRT-PCR, we compared the expression levels
of genes for collagen (Col1a1, Col1a2, and Col1a3) and
collagen synthesis enzymes (P4ha1, P4ha2, P4ha3, P4hb,
Plod1, Plod2, Plod3, heat shock protein 47, Adamts2,
Lox, Loxl1, and Loxl2) among directly isolated fibroblasts
of saline-treated lungs, fibroblasts of bleomycin-injured
lungs, and myofibroblasts of bleomycin-injured lungs
(Additional file 1: Table S3). As shown in Figure 8 and
Table 3, the expression levels of Col1a1, Col1a2, P4ha3,
Plod1, Plod2, Lox, and Loxl2 were significantly higher
(fold change > 2.0, P < 0.05) in fibroblasts and
myofibroblasts of bleomycin-injured lungs than in fibro-
blasts of saline-treated lungs. However, the expression
pattern of genes for collagen and collagen synthesis en-
zymes of myofibroblasts was similar to that of fibroblasts















Figure 5 Exploring cell surface markers of myofibroblasts and fibroblasts. (A) Snap-frozen bleomycin-injured lungs at day 12 were fixed in
acetone and examined by immunofluorescence using anti-α-SMA antibody (upper left), anti-CD49e antibody (upper right), and APC-conjugated
anti-Sca-1 antibody (lower left); the three images were merged (lower right). Arrows indicate a myofibroblast. Figures show representative results.
Scale bars indicate 100 μm. (B) Snap-frozen bleomycin-injured lungs at day 12 were fixed in acetone and examined by immunofluorescence with
DAPI (upper left), FITC-conjugated antibodies to lineage-specific cell surface markers (CD31, CD45, EpCAM, TER119, CD146, and Lyve-1) (upper
right), and PE-conjugated anti-Sca-1 antibody (lower left); the three images were merged (lower right). Arrows indicate cells that were localized in
the adventitia of the pulmonary artery and that were negative for lineage-specific cell surface markers (upper right) but positive for Sca-1 (lower
left). Figures show representative results. Scale bars indicate 50 μm. DAPI, 4′,6-diamidino-2-phenylindole.
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bleomycin-injured lungs to produce type 1 collagen
might be similar, but was greater than that of fibroblasts
of saline-treated lungs.
Many cell types, including fibroblasts, secrete various
chemokines to recruit inflammatory cells to injured le-
sions [31]. To our knowledge, at least 11 chemokines
(Ccl2, Ccl5, Ccl7, Ccl11, Cxcl1, Cxcl2, Cxcl5, Cxcl10,
Cxcl12, Cxcl14, and Cx3cl1) (Additional file 1: Table S3)
are secreted by lung fibroblasts in vivo or in vitro, as
shown in previous studies [32-40]. Figure 8 and Table 3
show the expression levels of 11 chemokine genes of
the three types of directly isolated cell. Interestingly,
the expression levels of eight chemokine genes ofmyofibroblasts were decreased when compared with
those of fibroblasts of bleomycin-injured lungs.
Taken together, the qRT-PCR results suggest that fibro-
blasts of saline-treated lungs, fibroblasts of bleomycin-
injured lungs, and myofibroblasts are functionally different.
Expression profiling of genes of directly isolated
myofibroblasts and cultured fibroblasts
After isolated fibroblasts of saline-treated lungs had been
cultured for 7 days, the cells differentiated into α-SMA-
positive myofibroblast-like cells in the presence of TGF-
β1. Because it is unknown whether the gene expression
pattern of cultured cells is altered by the effect of culture



























Figure 6 Identification of myofibroblast-rich and fibroblast-rich populations. (A) Flow cytometry plots showing the expression of CD49e
(x-axis) and Sca-1 (y-axis) of linneg cells of saline-treated lungs (left) and bleomycin-injured lungs at day 12 (right). Linneg Sca-1high of saline-treated
lungs (population A) and bleomycin-injured lungs at day 12 (population B) are indicated as circles. Linneg Sca-1low CD49ehigh of bleomycin-injured
lungs at day 12 (population C) and linneg Sca-1low CD49elow of bleomycin-injured lungs at day 12 (population D) are indicated as oblongs. Figures
show representative results. (B) Histogram showing the expression levels of intracellular α-SMA of populations A, B, C, and D using FITC-conjugated
anti-α-SMA antibody. As a control, FITC-conjugated isotype control antibody was used. Figures show representative results. (C) Sorted cells from
populations A, B, C, and D were grown for 36 h, fixed in 4% paraformaldehyde, and subjected to immunocytochemistry using anti-α-SMA antibody
(green), anti-vimentin antibody (red), and DAPI (blue). Phase-contrast images of living cells are shown in lower panels. Figures show representative results.
Scale bars indicate 100 μm. DAPI, 4′,6-diamidino-2-phenylindole.
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broblasts of saline-treated lungs that had been cultured
in the presence of TGF-β1. As expected, among the
three types of cell, the gene expression pattern of cul-
tured myofibroblast-like cells was most similar to that of
directly isolated myofibroblasts but many genes weredifferentially expressed between the cell types (Figure 9
and Table 4).
The expression patterns of collagen genes (Col1a1,
Col1a2, and Col3a1) and most chemokine genes were
different, indicating that in-vitro culture conditions af-
fected gene expression.






























Figure 7 In-vitro and in-vivo proliferative capacity of
myofibroblasts and fibroblasts. (A) Two hundred sorted cells from
populations A, B, and C were grown in 12-well plates. The graph
represents the number of adherent cells of each population, which
were counted on days 1, 4, 7, and 10 after sorting. Experiments were
performed in triplicate. Results represent the mean (± s.d.) of three
experiments. *, P < 0.01. (B) The left figure shows the cell-cycle
distribution of the DNA histogram from Hoechst 33342-stained cells
of population A. The high peak on the left side represents cells in
the G0G1 phase, and the low peak on the right side represents cells
in the G2M phase. The region between the two peaks represents
cells in the S phase. The proportion of cells in the G2M phase was
compared among lineage-specific cell surface marker-positive cells
of saline-treated lungs (lineage-positive cells of saline-treated lungs),
and populations A, B, and C (right). The bar graph represents the
proportion of cells in the G2M phase. Experiments were performed
in triplicate. Results represent the mean (± s.d.) of three experiments.


























































Figure 8 Expression profiling of genes for collagen, collagen
synthesis enzymes, and chemokines of directly isolated cells.
Cluster and dendrogram analyses were performed among three
types of directly isolated cells, that is, fibroblasts of saline-treated
lungs (SF1, SF2, and SF3), fibroblasts of bleomycin-injured lungs at
day 12 (BF1, BF2, and BF3), and myofibroblasts of bleomycin-injured
lungs at day 12 (M1, M2, and M3). QRT-PCR was performed in
triplicate using three independently prepared RNA samples. The
original raw data are shown in Additional file 1: Tables S4 and S5.
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On the basis of the information obtained from qRT-
PCR, immunofluorescence, flow cytometry, and cell
culture experiments, we demonstrated that fibroblasts
and myofibroblasts of saline-treated lungs and bleo-
mycin-injured lungs in the proliferative phase were
enriched in the linneg Sca-1high population and in the
linneg Sca-1low CD49ehigh population, respectively. Ap-
proximately 46,000 ± 17000 cells (N = 3) cells of a
fibroblast-rich population can be isolated from a lung of a
saline-treated mouse and approximately 34,000 ±
15000cells (N = 3) cells of a fibroblast-rich population and
16,000 ± 5000cells (N = 3) cells of a myofibroblast-rich
population can be isolated from a lung of a bleomycin-
injured mouse using this isolation method. Because in-vitro
culture conditions affected gene expression (Figure 9), it isreasonable to postulate that the global gene expression
signature of directly isolated cells by FACS reflects the
in-vivo transcriptional state more closely than that of
cultured cells.
Bleomycin-injured lungs of mice differ from human
idiopathic pulmonary fibrosis (IPF) lungs in their histo-
logical and pathological features [41,42]. For example, fi-
broblastic foci, which are histological hallmarks of IPF,
are rarely found in bleomycin-injured lungs. Fibroblastic
foci consist of myofibroblasts in myxomatous stroma
and are used to distinguish IPF from other interstitial
pneumonias. Immunohistochemical analysis demon-
strated that CD49e was expressed in myofibroblasts in
most fibroblastic foci of human IPF, as shown in a previ-
ous study (Additional file 1: Figure S5D) [43]. However,
Table 3 Differentially expressed genes among three types of directly isolated cell
B fibroblasts/S fibroblasts Myofibroblasts/S fibroblasts Myofibroblasts/B fibroblasts
Gene Fold change Gene Fold change Gene Fold change
Col1a1 2.97 Col1a1 3.91 P4ha2 2.68
Col1a2 2.05 Col1a2 2.28 Adamts2 0.42
Col3a1 3.02 P4ha2 2.68 Ccl5 0.32
P4ha3 11.76 P4ha3 21.01 Ccl7 0.19
Plod1 2.43 P4hb 2.49 Ccl11 0.02
Plod2 2.23 Plod1 2.30 Cxcl1 0.12
Lox 5.90 Plod2 2.88 Cxcl2 0.27
Loxl2 2.69 Plod3 2.06 Cxcl5 0.11
Ccl2 2.27 Lox 8.08 Cxcl10 0.49







Differentially expressed genes in fibroblasts of bleomycin-injured lungs at day 12 (B fibroblasts) relative to fibroblasts of saline-treated lungs (S fibroblasts),
myofibroblasts of bleomycin-injured lungs at day 12 relative to S fibroblasts, and myofibroblasts relative to B fibroblasts by a factor of > 2.0 or < 0.5 and P < 0.05.
QRT-PCR was performed in triplicate using three independently prepared RNA samples. Results represent the mean of three experiments.
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the fibroblastic foci and endothelial cells. Therefore, an
appropriate combination of cell surface markers should
be required for isolating myofibroblasts in fibroblastic
foci of IPF (Additional file 1: Figure S5E).
In addition, an immunohistochemical analysis of a hu-
man IPF lung demonstrated that CD49e was not expressed
in myofibroblasts within a fibrotic scar (Additional file 1:
Figure S5I), indicating that myofibroblasts might be divided
into two types in terms of the expression of CD49e, that is,
CD49e-positive myofibroblasts found in fibroblastic foci
and CD49e-negative myofibroblasts found within a
fibrotic scar. CD49e-positive and CD49-negative myo-
fibroblasts might represent young myofibroblasts and
mature myofibroblasts, respectively.
The bleomycin-injured lung model used in this study
has a limitation with regard to isolating myofibroblasts
at the remodeling phase because we failed to obtain
bleomycin-treated mice around days 21 and 28 after
treatment (Figure 1A). Typically, extensive fibrosis oc-
curs in bleomycin-injured lungs between 21 and 28
days after intratracheal administration of bleomycin, as
shown in previous studies [21,22]. Therefore, the sex,
age and body mass of the mice used and the amount of
bleomycin used for intratracheal administration should
be considered to obtain bleomycin-treated mice at the
remodeling phase [44].
It would be of interest to compare the biological char-
acteristics and gene signature of young myofibroblasts atthe proliferative phase with those of mature myofibroblasts
at the remodeling phase in bleomycin-injured lungs.
Similarly, the biological properties and gene signature of
CD49e-positive myofibroblasts of fibroblastic foci and
CD49e-negative myofibroblasts within fibrotic scars would
improve our understanding of the biology and pathology of
myofibroblasts in IPF lungs, in addition to other fibrotic
diseases.
In-vivo cell-cycle analysis using Hoechst 33342 showed
that the proliferative capacity of myofibroblasts of
bleomycin-injured lungs of day 12 was low and com-
parable with that of fibroblasts (Figure 7B). However,
only myofibroblasts did not have proliferative capacity
in vitro, as shown in Figure 7A. The difference of in-
vitro proliferative capacity between fibroblasts and myo-
fibroblasts leads us to assume that the optimal culture
conditions for the proliferation of myofibroblasts are
different from those of fibroblasts, including growth fac-
tors and oxygen levels in culture medium, and extra-
cellular matrix with which the surface of a culture plate
is coated.
Although the expression levels of most genes for
collagen and collagen synthesis enzymes were similar
between myofibroblasts and fibroblasts of bleomycin-
injured lungs at day 12 (Figure 8), some genes were dif-
ferentially expressed. The expression levels of P4ha2 and
P4ha3 of myofibroblasts were significantly higher than
those of fibroblasts of bleomycin-injured lungs (P4ha2;









































































Figure 9 Expression profiling of directly isolated
myofibroblasts and cultured fibroblasts. Cluster and dendrogram
analyses were performed among three types of directly isolated cells
(SF1, SF2, SF3, BF1, BF2, BF3, M1, M2 and M3) and myofibroblasts
cultured in the presence of TGF-β1 (TGF + 1, TGF + 2, TGF + 3).
QRT-PCR was performed in triplicate using three independently
prepared RNA samples. The original raw data are shown in
Additional file 1: Tables S4 and S5.
Table 4 Differentially expressed genes between cultured
















Differentially expressed genes in cultured fibroblasts (α-SMA-positive
myofibroblast-like cells) relative to directly isolated myofibroblasts by a factor
of > 2.0 or < 0.5 and P < 0.05. QRT-PCR was performed in triplicate using three
independently prepared RNA samples. Results represent the mean of
three experiments.
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of two identical α (isoenzymes P4ha1, P4ha2, and
P4ha3) and two β (P4hb) subunits and is essential for
the stability of the triple helix of collagen. Because P4h
is the rate-limiting enzyme of the pathway of posttrans-
lational modification of collagen, increased expressions
of P4ha2 and P4ha3 in myofibroblasts might result in
increased production of collagen.
We found that the expression levels of P4ha3 were
markedly increased in fibroblasts and myofibroblasts of
bleomycin-injured lungs (Table 3). However, immuno-
histochemical analysis demonstrated that the P4ha3
expression in bleomycin-injured lungs was markedly
increased in most cells, whereas its expression in saline-
treated lungs was low (Additional file 1: Figure S6), indi-
cating that the increased expression of P4ha3 was not
specific to fibroblasts and myofibroblasts of bleomycin-
injured lungs.The expression levels of Lox and Loxl2 were much
higher in myofibroblasts and fibroblasts of bleomycin-
injured lungs than in fibroblasts of saline-treated lungs
(Table 3), indicating that collagen produced by fibro-
blasts and myofibroblasts of bleomycin-injured lungs
might be easily cross-linked because of the increased
levels of Lox and Loxl2. A recent study showed that lung
fibrosis of mice induced by bleomycin, and liver fibrosis,
was inhibited by administration of anti-Loxl2 monoclo-
nal antibody [45]. In addition, previous studies of the ef-
fect of β-aminopropionitrile, an inhibitor of Lox, in lung
fibrosis models of rat and hamster have demonstrated
that bleomycin-induced fibrosis was attenuated by ad-
ministration of β-aminopropionitrile [46,47]. Thus, Lox
and Loxl2 might be useful targets for the development
of new antifibrotic drugs [48].
The origin of myofibroblasts remains controversial
[49]. Myofibroblasts have been thought to be a hete-
rogeneous population [7] composed of resident fibro-
blasts in the perivascular area [50], epithelial cells (by
epithelial-mesenchymal transition) [51], endothelial cells
(by endothelial-mesenchymal transition) [52], mesothe-
lial cells [53], and circulating fibrocytes derived from
bone marrow [54,55]. In this study, the heterogeneity of
myofibroblasts was not taken into account. Further in-
vestigations are needed to clarify the function of each
subpopulation of myofibroblasts.
Here, we demonstrated functional similarities and dif-
ferences among directly isolated fibroblasts of saline-
treated lungs, fibroblasts of bleomycin-injured lungs,
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Resident fibroblasts are activated on tissue injury and start
to express more genes for collagen and collagen synthesis
enzymes. After activated fibroblasts differentiate into
myofibroblasts, they continue to express genes for collagen
and collagen synthesis enzymes to the similar extent as acti-
vated fibroblasts. Myofibroblasts have a decreased ability to
express chemokine genes; however, the ability of collagen
production is conserved after differentiation.Conclusions
In this study, we report a direct method for isolating
myofibroblasts and fibroblasts from bleomycin-injured
lungs in mice at day 12 after injury. We demonstrated dif-
ferences in the proliferative capacity between fibroblasts
and myofibroblasts directly isolated from fibrotic lungs.
Analysis of the expression levels of genes for collagen, colla-
gen synthesis enzymes, and chemokines indicated func-
tional similarities and differences between myofibroblasts
and fibroblasts. The direct isolation method provides useful
information for a better understanding of the biologicalFibrocyte
Bone Marrow
Fibroblast Activated Fibroblast
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Figure 10 Model of myofibroblast development. Resident fibroblasts ar
more collagen and chemokines. After activated fibroblasts differentiate into
chemokines, as do fibroblasts and activated fibroblasts. Other types of cell,




This study was approved by the Animal Care and
Use Committee of Hamamatsu University School of
Medicine. All animal experiments were performed in ac-
cordance with the guidelines for animal experiments of
Hamamatsu University School of Medicine. All efforts
were made to minimize the number of animals used and
any discomfort.
C57BL/6 mice were purchased from Japan SLC
(Shizuoka, Japan), and NG2DsRedBAC transgenic mice
were purchased from Jackson Laboratory (Bar Harbor,
ME). The mice were maintained in a pathogen-free
mouse facility. Female C57BL/6 mice of 10 to 12 weeks
of age (20 to 25 g body mass) were intraperitoneally
anesthetized using pentobarbital sodium (Kyoritsu
Seiyaku Co, Tokyo, Japan) (77.8 μg/g body mass),
followed by a single intratracheal injection of 2 mg/kg





Collagen synthesis  
related enzyme  ↑
Chemokine ↓
Mesothelium
e activated when the tissue is injured, and then begin to produce
myofibroblasts, they still produce collagen, but they do not produce
such as mesothelial cells, endothelial cells, epithelial cells, and
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of mice treated with bleomycin decreased after ad-
ministration of bleomycin. Mice were killed by cervi
cal dislocation on day 12 after bleomycin or saline
treatment.
Hydroxyproline assay
Changes of lung collagen were determined by analysis of
hydroxyproline according to the manufacturer’s instruc-
tions with modifications (BioVision, Milpitas, CA).
Lungs were harvested on day 12 after bleomycin or sa-
line treatment and homogenized in distilled water, using
100 μl for every 10 mg of tissue. 160 μl 7.5 N HCl was
added to 40 μl sample homogenate, and hydrolyzed in a
pressure-tight vial at 120°C for 3 hours in a dry heat
oven. We then followed the manufacturer’s instructions.
Bronchoalveolar lavage (BAL) fluid
After mice were killed, the trachea was cannulated using
a 20-gage catheter. BAL was performed twice with 1.0
ml of ice-cold PBS with an 80% recovery rate. The BAL
fluid was centrifuged, and supernatant was collected.
Total cells were counted on a hemocytometer in the
presence of 0.4% trypan blue (Sigma-Aldrich, St Louis,
MO). For differential cell counting, cells were smeared
on glass slides, fixed, and stained with Giemsa solution.
The number of macrophages, neutrophils and lympho-
cytes in 400 cells was counted based on morphology.
Analysis of cytokines in BAL fluid
The concentrations of IL-6 and TGFβ1 in BAL fluid
were determined by ELISA (R&D systems, Minneapolis,
MN).
Antibodies
The primary antibodies used in this study were pur-
chased from eBioscience (San Diego, CA), Biolegend
(San Diego, CA), Miltenyi Biotechnology (Bergisch
Gladbach, Germany), Abcam (Cambridge, UK), Sigma-
Aldrich (St Louis, MO), Santa Cruz Biotechnology
(Dallas, TX), Millipore (Billerica, MA), Cell Signaling
Technology (Danvers, MA), DakoCytomation (Carpinteria,
CA), Molecular Probes (Grand Island, NY), and Epitomics
(Burlingame, CA). Detailed information on the antibodies
is shown in Additional file 1: Table S1.
Immunofluorescence
After lungs of C57BL/6 mice in optimal cutting
temperature compound (Sakura Finetek, Tokyo, Japan)
had been frozen at −80°C in organic solvent, 6 μm
thick slices, sectioned at −20°C using a cryostat, were
fixed in cold acetone for 10 min and dried for 20 min
at room temperature. After lungs of NG2DsRedBAC
transgenic mice had been fixed in 10% bufferedformalin overnight, 6 μm thick slices sectioned at −20°C,
using a cryostat, were dried for 20 min at room
temperature. The sections were incubated in blocking
solution (10% goat serum in PBS) for 30 min at
room temperature, and then incubated with primary
antibody and 1 μg/ml 4′,6-diamidino-2-phenylindole
(DAPI) (Sigma-Aldrich) in blocking solution for 30
min at room temperature, and then washed in PBS.
The sections were incubated with unconjugated pri-
mary antibody followed by incubation with Alexa-fluor
conjugated secondary antibody. The sections were
mounted in Prolong Gold (Molecular Probes) and im-
aged with Olympus BX51 fluorescence microscope
(Olympus, Tokyo, Japan). Images were captured with a
DP71 CCD camera (Olympus), processed with DP
control and DP manager software (Olympus), and then
postprocessed with Adobe Photoshop CS3 (Adobe
Systems, Inc., San Jose, CA).
Immunohistochemistry
Lungs were fixed in 10% buffered formalin, embedded in
paraffin, and sectioned to 4 μm thick slices. After the
sections were deparaffinized, they were initially incu-
bated in 3% hydrogen peroxide solution for 20 min at
room temperature. Antigen retrieval was performed
according to the manufacturer’s instructions. The sec-
tions were incubated with primary antibody in blocking
solution (10% goat serum and 0.1% Triton X-100 in
PBS) for 30 min at room temperature. After washing in
PBS, the sections were incubated with peroxidase-
conjugated universal immuno-enzyme polymer, anti-
mouse or anti-rabbit solution (Nichirei Biosciences),
and then visualized by 3,3-diaminobenzidine (Sigma-Al-
drich), and counter-stained with hematoxylin.
Fluorescence activating cell sorting (FACS)
Fat tissue, bronchus, pulmonary veins, and arteries were
removed from lungs. The lungs were incubated with 200
U/ml collagenase type 2 (Worthington, Lakewood, NJ)
and 100 U/ml DNase 1 (Worthington) for 30 min at
37°C in Dulbecco’s PBS (Gibco, Carlsbad, CA) and cut
using a gentleMACSTM Dissociator (Miltenyi Biotech-
nology) according to the manufacturer’s instructions.
After cells were filtered through a nylon screen (BD
Bioscience, San Diego, CA) to remove cell aggregates of,
cells were centrifuged and rinsed twice by FACS buffer
(1% HEPES buffer, 2% heat-inactivated FCS, 120 μg/ml
penicillin, 100 μg/ml streptomycin in HBSS). Cells were
incubated with biotin-conjugated anti-CD49e antibody
(×150), PE-Cy7-conjugated anti-Sca1 (×600) antibody,
and antibodies against lineage-specific cell surface
markers, that is, FITC-conjugated anti-CD146 antibody
(×10), FITC-conjugated anti-Lyve-1 antibody (×100),
APC-conjugated anti-EpCAM antibody (×100), APC-
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anti-CD45 antibody (×100), and APC-conjugated anti-
TER119 antibody (×100) for 30 min on ice. After centri-
fuging and rinsing twice in FACS buffer, the cells were
incubated with PerCP-Cy5.5-conjugated streptavidin
(×300) for 30 min on ice. After centrifuging and rinsing
twice by FACS buffer, all sorting and analysis were
performed on a FACSAria (BD Bioscience). To obtain
higher purity, the sorted sample was subjected to a sec-
ond round of sorting. The isotype antibodies were used
as a control experiment.
To analyze cell-cycle status using Hoechst 33342, cells
were incubated with 1 μg/ml Hoechst 33342 (Sigma-
Aldrich) and 50 μg/ml verapamil (Sigma-Aldrich) to
block MDR-mediated Hoechst efflux [57]. Cells were in-
cubated for 45 min at 37°C and agitated every 5 min to
prevent settling. After incubation, the cells were put on
ice and incubated with antibodies as described above.
Hoechst staining of cells was assayed by flow cytometry.
The formula for calculation of the proportion of cells in
the G2M phase is:
G2M% ¼ ðNumber of cells in the G2M phase = Number of
cells in the G0G1; S; and G2M phases combinedÞ
 100
Quantitative RT-PCR
Total RNA was extracted from 5,000 freshly isolated
cells using Trizol (Invitrogen) with glycogen as a carrier.
RNA was extracted following the manufacturer’s instruc-
tions. The extracted RNA was treated for 20 min at 37°C
with RNase free DNase 1 (Ambion, Austin, TX) in the
presence of RNase inhibitor (Invitrogen, Carlsbad, CA).
The RNA was purified with RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s in-
structions. After first-strand cDNA had been synthesized
by SuperScript Reverse Transcriptase (Invitrogen) with
random primers (Invitrogen), cDNA equivalent to 100
cells was used for each PCR reaction. Gene-specific
primers were designed by Primer 3 (v.0.4.0) software
[58] to generate short amplicons (100 to 150 bps). The
PCR reactions were performed using a SYBR Green
qRT-PCR Kit (Applied Biosystems, Foster City, CA).
The sequences of the gene-specific primers are shown in
Additional file 1: Tables S2 and S3.
The PCR cycling program consisted of one cycle of
95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for
one min, and one cycle of 95°C for 15 s and 60°C for
one min (ABI StepOnePlus). The cycle threshold (Ct)
for each gene was measured. cDNA equivalent to ten
cells was used to measure Ct of 18 s ribosomal RNA
(rRNA). The QRT-PCR products were separated in 2%
agarose gels to confirm the presence of a single band of
the expected size. QRT-PCR was performed in triplicateusing three independent RNA samples. However, qRT-
PCR for 114 genes (Table 1 and Additional file 1: Table
S2) was performed in duplicated using two independent
RNA samples.
To estimate the relative difference in gene expression
between samples, we assumed that the efficiency of
amplification was 90%, a typical value [59,60]. The
formula for fold change in a gene levels between
samples is:
Fold change = 1.8x
where:
x ¼ ðCt of a gene of sample A
− Ct of 18s rRNA of sample AÞ
−ðCt of a gene of sample B
− Ct of 18s rRNA of sample BÞ
Hierarchical clustering analysis was conducted on the
log2-transformed fold change values of qRT-PCR using
Cluster 3.0 software [61]. The results of clustering ana-
lysis were presented in the form of a dendrogram using
Java TreeView software [62,63].
Quantification of intracellular proteins
Isolated 10,000 linneg cells were centrifuged and fixed in
10% buffered formalin for 15 min at room temperature,
and then permeabilized for 5 min using IntraPrep
(Beckman Coulter, Brea, CA), according to the manufac-
turer’s instructions. After centrifuging and rinsing in FACS
buffer, the cells were incubated with FITC-conjugated
anti-α-SMA antibody for 30 min at room temperature.
After centrifuging and rinsing in FACS buffer, FITC
fluorescence intensity of cells was measured using the
FACSAria. Cells were incubated with unconjugated anti-
vimentin antibody (rabbit monoclonal) followed by
incubation with Alexa-fluor 488-conjugated anti-rabbit
antibody for 30 min at room temperature. Flow cytometry
analysis was performed in triplicate using three independ-
ent samples.
Cell culture and immunocytochemistry
Isolated batches of 200 cells were grown in DMEM
(Gibco) supplemented with 1× Glutamax (Gibco), 120
μg/ml penicillin, 100 μg/ml streptomycin, and 20% heat-
inactivated FCS (Gibco) on 12-well culture plates
(CELLSTAR, Greiner bio-one, Kremsmünster, Austria)
at 37°C under 5% CO2 in the absence or presence of
TGF-β1 (10 ng/ml) (R&D Systems). On days 1, 4, 7 and
10 after sorting, adherent cells were fixed in 4% parafor-
maldehyde for 10 min at room temperature and stained
with 1.0 μg/ml DAPI. Cell counting was performed in
triplicate using three independent samples.
For immunocytochemistry, isolated batches of 8,000
cells were grown for 36 hours in a 24-well plate, and
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min at room temperature, permeabilized with 0.5%
Triton X-100 in PBS for 5 min at room temperature,
and incubated in blocking solution (10% goat serum
and 0.1% Triton X-100 in PBS) for 30 min at room
temperature, and then incubated with unconjugated
anti-α-SMA antibody and unconjugated anti-vimentin
antibody followed by incubation with Alexa-fluor 488-
conjugated anti-mouse IgG2a antibody and Alexa-fluor
546-conjugated anti-rabbit antibody. Cells were imaged
with an Olympus IX71 fluorescence microscope (Olympus).
Images were captured with a DP70 camera (Olympus), and
then postprocessed with Adobe Photoshop CS3.
Statistical analysis
The data shown represent the means ± standard devi-
ation (s.d.) of at least three independent experiments.
Statistical analysis is performed using an unpaired Stu-
dent’s t test (two-tailed). P < 0.05 is considered statisti-
cally significant.
Additional file
Additional file 1: Figure S1. CD146 expression in lung. Figure S2.
CD146 is a lineage-specific cell surface marker of NG2-positive pericytes
and vascular smooth muscle cells in lung. Figure S3. FACS gating
strategy. Figure S4. CD49e and Sca-1 are not expressed in mesothelial
cells. Figure S5. Expression levels of α-SMA, Col1A1, CD49e, and lineage-
specific cell surface markers in myofibroblasts in lung with IPF. Figure S6.
Increased expression levels of P4ha3 in many cell types in bleomycin-
injured lungs. Table S1. Antibodies used. Table S2. Details of 114 genes
for cell surface markers. Table S3. Details of genes for collagen, collagen
synthesis enzymes, and chemokines. Table S4. Raw qRT-PCR data of
genes for collagen and collagen synthesis enzymes of the different cell
types. Table S5. Raw qRT-PCR data of chemokine genes of the different
cell types.
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